Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.73 (urokinase-type plasminogen activator)
 10,685 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Colon tumor cells are more responsive to certain growth modulators in their local environment in vivo than are normal colonocytes. Examples of this class of compounds are the fecal diglycerides (DGs)(E. Friedman et al., Cancer Res., 49: 544-548, 1989), which may act as endogenous tumor promoters. At the concentration found in vivo, fecal DGs composed of oleic, myristic, and palmitic fatty acids induced mitogenesis of all classes of benign tumor cells and of half of the resected carcinomas tested in primary culture, but induced no detectable mitogenesis of normal colonocytes. Colon tumor cells also exhibit selective responses to these endogenous modulators as measured by another biological parameter, secretion of urokinase from carcinomas than from normal colonocytes. Fecal DGs also induced a 13-fold increase in urokinase mRNA synthesis in colon carcinoma cells and induced secretion of active urokinase from each of five resected carcinomas. Colon carcinomas, at both the primary site and metastatic to the liver, secreted the Mr 55,000 form of urokinase constitutively and secreted the same form upon treatment with fecal DGs. An increase in the steady-state level of urokinase secretion by saturated-chain DGs exhibited a strong dependency on the chain length of the fatty acid residues, those of 14 and 16 carbons having the greatest activity. Thus, fecal DGs composed of oleic, myristic, and palmitic acid residues induce two biological activities selectively in colon tumor cells, each of which would enhance tumor development. Selective mitogenesis would increase adenoma and carcinoma cell number relative to normal colonocyte number, and induction of the proteolytic enzyme urokinase would aid local invasion of the carcinoma within the bowel wall.
 ...
PMID:Urokinase secretion from human colon carcinomas induced by endogenous diglycerides. 210 72

This study documents the ability of substrata material derived from well but not poorly differentiated colon carcinoma cells to alter the biological characteristics of a separate colon carcinoma cell line (MOSERSF). To assess changes induced by the presence of these substrata, MOSERSF cells were screened for (a) morphological features, (b) secretion of carcinoembryonic antigen (CEA), (c) alteration of urokinase levels, and (d) sensitivity to the growth-inhibitory peptide transforming growth factor beta. Morphologically, MOSERSF cells grown on plastic displayed a rounded shape and could be detached by agitation. Subculturing of these cells onto substrata laid down by well differentiated (mature) colon carcinoma cells resulted in cell attachment and spreading. These changes did not manifest themselves when cells were plated on material derived from poorly differentiated (primitive) colon cells. Conditioned medium from MOSERSF cells grown on plastic or on colon-derived material from the well and poorly differentiated colon cells were compared for CEA levels. Substrata derived from undifferentiated cells were without effect on assayable CEA (substrata absent, 1.4 ng/ml/10(6) cells/72 h; substrata present, 1.4-1.7 ng/ml/10(6) cells/72 h). However, growth of MOSERSF cells on material deposited by well differentiated colon cells resulted in a 3-fold increase in the level of CEA. Spent medium was also analyzed for urokinase. A high level of the protease (20.3 ng/ml/10(6) cells/72 h) was expressed by MOSERSF cells. The concentration of the enzyme was reduced by over 50% when MOSERSF cells were propagated on substrata laid down by well differentiated cells. An enhanced sensitivity to the growth-retarding effects of transforming growth factor beta was seen with certain substrata. On plastic, transforming growth factor beta inhibited proliferation of MOSERSF cells with a median effective concentration of 0.65 ng/ml. However, on substrata from mature but not primitive cells, MOSERSF cells exhibited an increased sensitivity to the peptide (median effective concentration, 0.16 ng/ml). Colon-derived material obtained from both well differentiated and poorly differentiated colon carcinoma cells was compared after [35S]-methionine metabolic labeling. More [35S]methionine was incorporated into the material from the "mature" colon cells. The substrata could also be distinguished by quantitative differences in a number of high molecular weight proteins. Immunofluorescence of colon-deposited material revealed the presence of laminin and fibronectin.
 ...
PMID:Alterations of the biological characteristics of a colon carcinoma cell line by colon-derived substrata material. 316 26

A case of generalized peritonitis, secondary to a perforation of the rectosigmoid colon during barium-enema roentgenography, is presented. The patient required immediate surgical intervention with the prime importance of the treatment being removal of as much of the contaminating materials as possible. This was done successfully with irrigation and wiping, using urokinase solution. Peritoneal lavage with urokinase solution was also carried out in the early postoperative period. Fluid replacement with careful monitoring of fluid and electrolyte balance is essential before, during, and after the surgical procedure. Adequate antibiotic therapy and careful respiratory and nutritional support are also important.
Dis Colon Rectum 1985 May
PMID:Barium peritonitis. Report of a case and review of the literature. 399 52

Portal vein thrombosis is a rare complication in ulcerative colitis. We present a patient with portal vein thrombosis in ulcerative colitis who was successfully treated with colectomy. A 38-year-old Japanese female was admitted to our hospital because of an exacerbation of colitis. Abdominal ultrasonography performed because of liver dysfunction showed the thrombus in an umbilical portion of the portal vein. The patient underwent a subtotal colectomy and ileostomy because her colitis did not respond to intensive intravenous therapy. Although portal vein thrombus was treated with an intravenous infusion of urokinase before the operation, no change in the thrombus size was found. Approximately three months after the colectomy, the thrombus of the portal vein disappeared without anticoagulant therapy. Although a resection of an inflamed colon may be theoretically effective in the thrombosis in the inflammatory bowel disease, its benefit has not been confirmed. Our case suggests that the resection of the diseased bowel may have a favorable effect on the course of portal vein thrombosis in acute attacks of ulcerative colitis.
Dis Colon Rectum 2001 Apr
PMID:Portal vein thrombosis successfully treated with a colectomy in active ulcerative colitis: report of a case. 1133 May 88